Efficacy of suplatast tosilate for treatment of atopic dermatitis poorly controlled by other anti-allergic drugs

Yumi Matsumura, Yoshiki Miyachi, Yoshinari Matsumoto, Shun Kitaba, Ichiro Katayama, Akiko Kishioka, Fukumi Furukawa, Yasuo Kubota, Gen Nakanishi, Keiji Iwatsuki, Sakae Kaneko, Eishin Morita, Kunio Izu, Yoshiki Tokura, Shuji Fukagawa, Masutaka Furue, Motoi Takenaka, Shinichi Sato, Kazumoto Katagiri

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The Th2 cytokine inhibitor, suplatast tosilate 300mg/day was administered to 163 patients with atopic dermatitis who had been poorly controlled by other anti-allergic drugs. The usefulness of suplatast tosilate was evaluated witfi respect to skin symptom score and parameters such as IgE, eosinophil and basophil counts, and LDH. After 4 weeks of treatment, the skin symptom score, eosinophil counts and LDH were significantly decreased, whereas other parameters remained unchanged.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalSkin Research
Volume6
Issue numberSUPPL. 8
Publication statusPublished - Mar 1 2007

    Fingerprint

Keywords

  • Atopic dermatitis
  • Skin symptom score
  • Suplatast tosilate

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Cite this

Matsumura, Y., Miyachi, Y., Matsumoto, Y., Kitaba, S., Katayama, I., Kishioka, A., Furukawa, F., Kubota, Y., Nakanishi, G., Iwatsuki, K., Kaneko, S., Morita, E., Izu, K., Tokura, Y., Fukagawa, S., Furue, M., Takenaka, M., Sato, S., & Katagiri, K. (2007). Efficacy of suplatast tosilate for treatment of atopic dermatitis poorly controlled by other anti-allergic drugs. Skin Research, 6(SUPPL. 8), 1-7.